Industry news that matters to you.  Learn more

Stromedix Expands its Fibrosis Pipeline Through In-Licensing Agreement with UCSF

Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin alpha-v-beta-5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco (UCSF). Preclinical research suggests that alpha-v-beta-5 plays an important role in a variety of acute and chronic organ failure settings.

Research Universities and Big Pharma’s Wicked Problem

A few years ago BP awarded a consortium of universities led by Berkeley the largest grant in University of California history: $500 million over ten years to develop biofuels. Despite BP’s well-publicized travails, their commitment to the Energy Biosciences Institute remains firmly in place.

Penn Researchers Receive $12 Million NIH Grant to Develop Personalized Approach to Smoking Cessation

A variety of smoking cessation treatments are currently available for the more than 18 million adult Americans try to quit smoking each year, but success rates vary widely. Despite the importance of quitting smoking, more personalized approaches to smoking cessation treatment are needed to help smokers pick the right method that will work best for them. A major new personalized medicine clinical trial, led by addiction researchers at the University of Pennsylvania, will study how a smokers’ genetic make-up influences their quitting success.

Multiple biomarker index useful only in asymptomatic patients with mild atherosclerosis

A multiple biomarker index, one that includes markers of inflammation, is only modestly associated with increased risks of coronary heart disease and cardiovascular disease in asymptomatic patients, according to the results of a new study [1]. The increased risk of events for patients with a biomarker score above the median occurs mainly in those with a mild amount of existing atherosclerosis, according to investigators.

UC San Diego Brain Tumor Treatment Program Launches Personalized Biomarker Clinical Study

The Brain Tumor Unit at the Moores UCSD Cancer Center at the University of California, San Diego in La Jolla, is launching a clinical trial that will examine the use of biomarkers to advance the treatment of malignant gliomas, brain tumors that start in the brain or spinal cord tissue. Annually, about 17,000 Americans are diagnosed with gliomas, which are difficult to treat and often fatal.